An Adjuvant for the Induction of Potent, Protective Humoral Responses to an H5N1 Influenza Virus Vaccine with Antigen-Sparing Effect in Mice

ABSTRACT Intramuscular administration of inactivated influenza virus vaccine is the main vaccine platform used for the prevention of seasonal influenza virus infection. In clinical trials, inactivated H5N1 vaccines have been shown to be safe and capable of eliciting immune correlates of protection. However, the H5N1 vaccines are poorly immunogenic compared to seasonal influenza virus vaccines. Needle-free vaccination would be more efficient and economical in a pandemic, and the development of an effective and safe mucosal adjuvant will be an important milestone. A stabilized chemical analog of double-stranded RNA, PIKA, was previously reported to be a potent mucosal adjuvant in a murine model. While PIKA stimulates dendritic cells in vitro, little was known about its receptor and adjuvanting mechanism in vivo. In this study, we demonstrated that the immunostimulatory effect of PIKA resulted in an increased number of mature antigen-presenting cells, with the induction of proinflammatory cytokines at the inoculation site. In addition, coadministration of PIKA with a poorly immunogenic H5N1 subunit vaccine led to antigen sparing and quantitative and qualitative improvements of the immune responses over those achieved with an unadjuvanted vaccine in mice. The adjuvanted vaccine provided protection against lethal challenge with homologous and heterologous H5N1 wild-type viruses. Mice lacking functional TLR3 showed diminished cytokine production with PIKA stimulation, diminished antibody responses, and reduced protective efficacy against wild-type virus challenge following vaccination. These data suggest that TLR3 is important for the optimal performance of PIKA as an adjuvant. With its good safety profile and antigen-sparing effect, PIKA could be an attractive adjuvant for use in future pandemics.

[1]  K. Subbarao,et al.  Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. , 2010, Virology.

[2]  X. Zhang,et al.  A novel influenza A (H1N1) vaccine in various age groups. , 2009, The New England journal of medicine.

[3]  C. Wichems,et al.  Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.

[4]  T. Ichinohe,et al.  PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. , 2009, Vaccine.

[5]  R. Rappuoli,et al.  Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin , 2009, PloS one.

[6]  Hideo Goto,et al.  In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses , 2009, Nature.

[7]  R. Steinman,et al.  Synthetic Double-Stranded RNAs Are Adjuvants for the Induction of T Helper 1 and Humoral Immune Responses to Human Papillomavirus in Rhesus Macaques , 2009, PLoS pathogens.

[8]  E. Ooi,et al.  A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic , 2009, Vaccine.

[9]  K. Subbarao,et al.  Avian Influenza H6 Viruses Productively Infect and Cause Illness in Mice and Ferrets , 2008, Journal of Virology.

[10]  K. Subbarao,et al.  A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. , 2008, Virology.

[11]  R. Rappuoli,et al.  Molecular and cellular signatures of human vaccine adjuvants , 2008, Proceedings of the National Academy of Sciences.

[12]  R. Riedl,et al.  The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. , 2008, Vaccine.

[13]  H. Ehrlich,et al.  A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. , 2008, The New England journal of medicine.

[14]  R. Steinman,et al.  The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine , 2008, Proceedings of the National Academy of Sciences.

[15]  R. Rappuoli,et al.  Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. , 2008, Vaccine.

[16]  K. Ishii,et al.  Cutting Edge: Cooperation of IPS-1- and TRIF-Dependent Pathways in Poly IC-Enhanced Antibody Production and Cytotoxic T Cell Responses , 2008, The Journal of Immunology.

[17]  T. Ichinohe,et al.  Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine , 2007, The Journal of infectious diseases.

[18]  T. Ichinohe,et al.  Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. , 2007, Microbes and infection.

[19]  G. Leroux-Roels,et al.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.

[20]  R. Couch,et al.  A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. , 2007, Vaccine.

[21]  Changyou Wu,et al.  PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA. , 2007, Cellular & molecular immunology.

[22]  L. Brown,et al.  Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. , 2006, International immunology.

[23]  K. Nichol,et al.  Vaccines for seasonal and pandemic influenza. , 2006, The Journal of infectious diseases.

[24]  B. Murphy,et al.  Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets , 2006, PLoS medicine.

[25]  D. Vidal,et al.  Resident CD11c+ lung cells are impaired by anthrax toxins after spore infection. , 2006, The Journal of infectious diseases.

[26]  M. Zambon,et al.  Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial , 2006, The Lancet.

[27]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[28]  Cécile Viboud,et al.  Antibody response to influenza vaccination in the elderly: a quantitative review. , 2006, Vaccine.

[29]  Angus Nicoll,et al.  Avian influenza A (H5N1) infection in humans. , 2005, The New England journal of medicine.

[30]  T. Ichinohe,et al.  Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection , 2005, Journal of Virology.

[31]  Yi Guan,et al.  Influenza: Emergence and Control , 2004, Journal of Virology.

[32]  P. Wright,et al.  Role of IgA versus IgG in the Control of Influenza Viral Infection in the Murine Respiratory Tract1 , 2004, The Journal of Immunology.

[33]  Yuping Deng,et al.  Age-Related Impaired Type 1 T Cell Responses to Influenza: Reduced Activation Ex Vivo, Decreased Expansion in CTL Culture In Vitro, and Blunted Response to Influenza Vaccination In Vivo in the Elderly1 , 2004, The Journal of Immunology.

[34]  G. Tannock,et al.  Route of administration is the prime determinant of IgA and IgG2a responses in the respiratory tract of mice to the cold-adapted live attenuated influenza A donor strain A/Leningrad/134/17/57. , 2003, Vaccine.

[35]  N. Kondo,et al.  Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. , 2003, Vaccine.

[36]  Maria Zambon,et al.  Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. , 2003, Vaccine.

[37]  L. Brown,et al.  Highly Immunogenic and Totally Synthetic Lipopeptides as Self-Adjuvanting Immunocontraceptive Vaccines1 , 2002, The Journal of Immunology.

[38]  M. Zambon,et al.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.

[39]  H. Heiken,et al.  The IgG Fc receptor family , 1998, Annals of Hematology.

[40]  Francesca Granucci,et al.  Maturation Stages of Mouse Dendritic Cells in Growth Factor–dependent Long-Term Cultures , 1997, The Journal of experimental medicine.

[41]  E. Rajnavölgyi,et al.  IgG isotype distribution of local and systemic immune responses induced by influenza virus infection , 1994, European journal of immunology.

[42]  C. Kaetzel,et al.  Intracellular neutralization of virus by immunoglobulin A antibodies. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[43]  B. Murphy,et al.  Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum , 1987, Journal of clinical microbiology.

[44]  J. Snick,et al.  IgG2a restriction of murine antibodies elicited by viral infections , 1987, The Journal of experimental medicine.

[45]  L. Brown,et al.  Antigenic determinants of influenza virus hemagglutinin. XII. the epitopes of a synthetic peptide representing the C-terminus of HA1. , 1986, Virology.

[46]  D. Jackson,et al.  Antigenic Determinants of Influenza Virus Hemagglutinin , 1979, The Journal of Immunology.

[47]  V. Devita,et al.  A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. , 1976, Journal of the National Cancer Institute.

[48]  H. Eisen,et al.  Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages , 1975, The Journal of experimental medicine.

[49]  Robert Schechter,et al.  Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[50]  M. Mason,et al.  A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. , 2009, Vaccine.

[51]  M. Kende,et al.  Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. , 1999, Vaccine.

[52]  M. Neuberger,et al.  Activation of mouse complement by monoclonal mouse antibodies , 1981, European journal of immunology.